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Stephen H. Petersdorf,1,2 Andrei R. Shustov,1,3 Mary E. D. Flowers,1,2 Paul O’Donnell,1,2
Brenda M. Sandmaier,1,2 Rainer F. Storb,1,2 Ajay K. Gopal1,2Reduced-intensity conditioning (RIC) before allogeneic hematopoietic cell transplantation (HCT) is increas-
ingly used as a potentially curative option for patients with advanced lymphoma; however, relapse remains
a major challenge. Unfortunately, little data are available on outcomes, predictors of survival, and results of
specific management strategies in these patients. In the present study, a total of 101 consecutive relapses oc-
curred and were evaluated in 280 patients with lymphoma who underwent RIC HCT. Diseases included ag-
gressive non-Hodgkin lymphoma (NHL) (n5 42), indolent NHL (n5 33), and Hodgkin lymphoma (HL) (n5
26). Median time to relapse was 90 days (range, 3-1275 days), and graft-versus-host disease at relapse was
present in 56 patients (55%). Interventions after relapse included no therapy (n5 14), withdrawal of immu-
nosuppression alone (n 5 11), chemoradiotherapy (n 5 60), and donor lymphocyte infusion/second HCT
(n 5 16). Overall survival (OS) was 33% (95% confidence interval [CI], 23%-44%) at 3 years after relapse
and 23% (95% CI, 13%-34%) at 5 years after relapse. Both aggressive NHL (vs indolent disease; hazard ratio,
2.29; P5.008) and relapse within 1 month post-HCT (vs.6 months; hazard ratio, 3.17; P5.004) were asso-
ciated with increased mortality. Estimated 3-year OS was 16% (95% CI, 5%-32%) after relapse for aggressive
NHL, 40% (95%CI, 19%-61%) after relapse for indolentNHL, and 47% (95%CI, 29%-64%) after relapse forHL.
The 1-year survival was 24% for patients relapsing within 1 month post-HCT, compared with 52% for those
relapsing at 1-3 months, 74% for those relapsing at 3-6 months, and 77% for those relapsing at more than 6
months. We conclude that despite relapse of lymphoma after RIC HCT, some patients may experience pro-
longed survival,with better postrelapseoutcomesoccurring in patientswith indolentNHL,HL, or late relapse.
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to be offered to a broader cohort of lymphoma patients
who are not candidates for myeloablative allogeneic
HCT [1-6]. This strategy has yielded long-term remis-
sions in heavily pretreated patients with a spectrum
of lymphoma histologies, along with lower early
nonrelapse mortality compared with myeloablative
regimens [7-9]. The prevention and management of
relapse remain challenging, however [2,10]. Without
a myeloablative regimen, the absence of high-dose
conditioningmay heighten the risk of early disease pro-
gression, yet if relapse occurs, the absence of recent in-
tensive therapy might not preclude the persistence of
chemotherapy-responsive disease.
We hypothesized that even after relapse, the alloge-
neic graft could provide a posttransplantation platform
of chemotherapy-na€ıve hematopoiesis for both myelo-
suppressive therapy and immune-mediated antitumor1537
1538 Biol Blood Marrow Transplant 17:1537-1545, 2011R. Ram et al.manipulations, augmenting the graft-versus-lymphoma
(GVL) effect and regaining disease control. Unfortu-
nately, despite the extensive use of this approach and
the frequent clinical challengeof treating lymphomatous
relapse afterRICandallogeneicHCT, little is known re-
garding the prognosis and predictors of outcome in this
setting. Published studies have typically described fewer
than 20 lymphoma patients or have focused on a subset
receiving a specific intervention, precluding an under-
standing of the group as a whole [11-14]. Here we
present the largest series to date, describing in detail
the outcomes of 101 consecutive lymphoma relapses
after RIC and allogeneic HCT, revealing factors that
are useful for counseling patients, and placing the
results of specific postrelapse interventions in context.
PATIENTS AND METHODS
Patients and Definitions
A total of 280 patients with non-Hodgkin lym-
phoma (NHL) or Hodgkin lymphoma (HL) who
underwent allogeneic HCT with RIC or nonmyeloa-
blative conditioning between 1999 and 2009 at the
Fred Hutchinson Cancer Research Center were
included in this analysis and evaluated for post-HCT
relapse. All patientswere conditionedwith 2Gyof total
body irradiation (TBI) given alone, in combination
with fludarabine (30 mg/m2 body surface area/day,
for 3 consecutive days), in combination with fludara-
bine and Y90 (ibritumomab tiuxetan), or in combina-
tion with fludarabine and cyclophosphamide [15-18].
Post-HCT immunosuppression includedmycopheno-
late mofetil and calcineurin inhibitor (cyclosporine or
tacrolimus) and, when an HLA-haploidentical donor
was used, cyclophosphamide, as described previously
[18-21]. Donors included either HLA-identical sib-
ling/unrelated, HLA-haploidentical, or 1 HLA anti-
gen‒mismatched donors. HLA typing was performed
with intermediate- or high-resolution molecular
matching for HLA-A, -B, -C, -DRB1, and -DQB1.
Diffuse large B cell lymphoma (DLBCL), blastoid
mantle cell lymphoma (MCL), T lymphoblastic lym-
phoma (TLBL), and peripheral T cell lymphoma
were categorized as aggressive NHL, whereas follicu-
lar lymphoma (FL), nonblastoid type MCL, marginal
zone lymphoma (MZL), and small lymphocytic lym-
phoma (SLL)/chronic lymphocytic leukemia (CLL)
were considered indolent NHL. Patients with HL
were included in a separate group. Pretransplantation
comorbidities were assessed using the HCT Comor-
bidity Index (HCT-CI) [22].
All patients provided written informed consent to
allow the use of medical information for research,
and an Institutional Review Board–approved protocol
was used to retrospectively gather data. Patients were
included in this analysis if they had disease relapse or
progression at any time after RIC HCT.Patient Evaluation
All patients underwent a pretransplantation base-
line computed tomography (CT) or CT/positron
emission tomography scan and bone marrow evalua-
tion to determine their pretransplantation remission
status. In addition, all patients had a surveillance CT
and/or positron emission tomography scan and
a bone marrow biopsy approximately 3 months after
allogeneicHCT. Further disease evaluations were typ-
ically performed 6 months after HCT and then at least
annually thereafter. Response and progression were
defined by standard criteria [23]. Disease progression
that included only detection of malignant cells in the
marrow or blood by flow cytometry, cytogenetic, or
molecular study was categorized as ‘‘minimal disease’’
relapse.
Postrelapse Interventions
Withdrawal of immunosuppressive therapy (IST)
included any unscheduled decrease in immunosup-
pression to treat relapse/progression. Chemoradiation
included chemotherapy (including rituximab) and/or
radiation therapy. Some of the patients in this group
also had withdrawal of IST. Immunologic strategies
included donor lymphocyte infusion (DLI) and second
allogeneic HCT. Patients in this group also could have
received chemoradiation and/or undergone with-
drawal of IST.
Statistical Analysis
Overall survival (OS) after relapse was estimated
using the Kaplan-Meier method, with day of relapse
serving as day 0. The association of factors with the
hazard of death after relapse was assessed by Cox re-
gression analysis. All 2-sided P values were estimated
using the Wald test without adjustments for multiple
comparisons. For each analysis, hazard ratios (HRs)
and 95% confidence intervals (95% CIs) are given to-
gether with P values for comparisons with the refer-
ence category. Because the choice of treatment for
relapse was influenced in part by patient and tumor
characteristics, the data on the impact of treatment
for relapse on postrelapse outcomes are provided in
descriptive form without statistical inference.RESULTS
Patient Characteristics
Relapse or progression occurred in 101 of the 280
patients in this series (36%), including 42 (42%) with
aggressive NHL (25 with DLBCL, 11 with blastoid-
type MCL, 2 with TLBL, and 4 with peripheral T
cell lymphoma), 33 (33%) with indolent NHL (22
with SLL/CLL, 5 with FL, 5 with classic MCL, and
1 with MZL), and 26 (26%) with HL. The median
Biol Blood Marrow Transplant 17:1537-1545, 2011 1539Lymphoma Relapse after RIC Allogeneic HCTtime from diagnosis to HCT was 3.4 years (range, 0.9-
24.7 years), and the median number of treatments be-
fore HCT was 4 (range, 1-8). Forty patients had
underwent autologous stem cell transplantation before
HCT (25 with aggressive NHL, 13 with HL, and 2
with indolent NHL). Before transplantation, 40 pa-
tients (40%) had chemotherapy-responsive disease,
and 37 (37%) had untreated progressive disease.
Table 1 summarizes the patient, disease, and transplan-
tation characteristics grouped by disease histology.Transplantation and Relapse Characteristics
Eighty patients (79%) were conditioned with low-
dose TBI with or without fludarabine, and 2 also re-
ceived cyclophosphamide. Twenty-one patients
(21%) received Y-90-Ibritumomab-tiuxetan in addi-
tion to TBI and fludarabine. HLA-matched donors
were utilized in 95 (94%) patients (Table 1). Fifty-six
patients had evidence of graft-versus-host disease
(GVHD) at the time of relapse, including 54 (53%)
with acute features and 22 (22%) with chronic features.
Relapse occurred after a median of 90 days (range,
3-1275 days) after HCT. Relapse occurred before 1
month in 21 patients, between 1 and 3 months in 31
patients, between 3 and 6 months in 21 patients, and
after 6 months in 28 patients (Figure 1). The median
time to relapse for patients with aggressive NHL was
1.3 months (range, 0.1-15.5 months), indolent NHL
was 3.4 months (range, 0.6-12.2 months), and HL
was 6.3 months (range 0.5-29.6 months). The majorityTable 1. Patient, Disease, and Transplantation Characteristics of
Allogeneic HCT
Aggres
Age, years, median (range) 57
Sex, male/female, n
HCT-CI >1, %*
Time from diagnosis to HCT, years, median (range) 2.5
Number of previous therapies, median, (range) 4
Maximal bulk of disease before transplantation, cm, mean (range) 2.9
Patients with pretransplantation chemoresponsive disease, n (%) 16
Pretransplantation remission status, n (%)
CR 5
PR 11
Stable disease 14
Progressive disease 12
Conditioning regimen, n (%)
TBI 3
Flu-TBI 27
Y90-Flu-TBI† 12
Donor type, n (%)
MRD 18
MUD 19
Haploidentical 2
MMUD 3
Acute GVHD before relapse, n (%) 19
Chronic GVHD before relapse, n (%) 2
Flu indicates fludarabine; MMUD, mismatched unrelated donor; MRD, matche
*Out of 99 patients with all available data.
†DLBCL, n 5 8; MCL, n 5 6; CLL, n 5 5; FL, n 5 2.of patients presented with measurable disease at the
time of relapse (88%, 76%, and 100%, respectively)
though 13 progressed with only ‘‘minimal‘‘ disease de-
tected by flow cytometry or molecular testing (7 with
CLL/SLL, 3 with TLBL, 1 with DLBCL, 1 with blas-
toid MCL, and 1 with FL). In patients with aggressive
NHL,median time to relapse was 1month (range, 0.1-
5.3 months) in those who underwent previous autolo-
gousHCT and 2.8 months (range, 0.1-15.5 months) in
those who did not. In patients withHL,median time to
relapse was 4.6 months (range, 0.5-6.3 months) in
those who underwent previous autologous HCT and
12 months (range, 3.6-29.6 months) in those who did
not. Neither CD3 nor CD33 donor chimerism was as-
sociated with time to relapse or subsequent survival.Overall Survival
Thirty-three of 101 patients were alive at a median
follow-up of 2.2 years (range, 0.2-8.1 years) from re-
lapse. The estimated OS from time of relapse in all pa-
tients was 33% (95%CI 23-44%) at 3 years post-HCT
and 23% (95% CI, 13-34%) at 5 years post-HCT.
Causes of death were lymphoma in 41 patients (60%)
and complications of postrelapse therapy in 27 patients
(40%). The estimated 3-year OS from relapse by his-
tology was 16% in patients with aggressive NHL
(95% CI, 5%-32%), 40% in patients with indolent
NHL (95% CI, 19%-61%), and 47% in patients
with HL (95% CI, 29%-64%) (Figure 2). The esti-
mated 1-year OS for patients who relapsed within 1101 Patients with Lymphoma Who Relapsed after RIC and
sive Lymphoma
(n 5 42)
Indolent Lymphoma
(n 5 33)
Hodgkin Lymphoma
(n 5 26)
(29-73) 59 (34-68) 31 (18-53)
28/14 22/11 15/11
21 42 42
(1.3-13.8) 4.8 (0.9-19.4) 3 (1.3-24.7)
(2-8) 3 (1-6) 5 (3-6)
(1-8.2) 4.2 (0-18.6) 2.7 (1-6.5)
(38) 10 (30) 14 (54)
(12) 0 (0) 1 (4)
(26) 10 (30) 13 (50)
(33) 6 (18) 4 (15)
(29) 17 (52) 8 (31)
(7) 6 (18) 8 (30)
(64) 18 (55) 18 (70)
(29) 9 (27) 0
(43) 20 (61) 14 (54)
(45) 12 (36) 12 (46)
(5) 0 0
(7) 1 (3) 0
(45) 20 (61) 15 (58)
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Figure 1. Distribution of relapses over time after RIC HCT by histol-
ogy.
Figure 3. OS of patients with relapse/progression after RIC HCT,
according to time to relapse.
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those who relapsed at 1 to\3 months, 74% for those
relapsing at 3-6 months, and 77% for those who re-
lapsed at .6 months (Figure 3). Fifteen of the 17 pa-
tients with aggressive NHL who relapsed within 1
month post-HCT died by 9 months, with a median
survival of 2.7 months. Among the patients with ag-
gressiveNHL, 20%of thosewhounderwent a previous
autologous HCT and 29% of those who did not are
currently alive. Among the patients with HL, 38% of
the patients who underwent a previous autologous
HCT and 31% of those who did not are currently
alive. Likewise, a landmark analysis of best response
in patients surviving to the day-84 assessment found
no association with survival after relapse. The absolute
HR for mortality for each response group was 0.98 for
patients in complete remission (CR), 1.09 for those in
partial remission (PR), and 1.19 for those with stable
disease, when patients with progressive disease were
used as the reference group.
Univariate and Multivariate Analysis
Univariate regression models identified aggressive
NHL (P 5 .0006 vs indolent NHL), absence of
chronic GVHD before relapse (P 5 .03), and relapse
within 1month post-HCT (P\.0001 vs.6months) as
factors associated with increased mortality (Table 2).
Chemoresponsive disease also was suggestively associ-
ated with the risk of mortality in a univariate modelFigure 2. OS of patients with relapse/progression after RIC HCT,
according to disease histology.(Table 2), but this significance was diminished after
adjusting for histology and time to relapse (HR, 0.69;
P 5 .15). In a multivariate model (Table 2), only ag-
gressive NHL and time to relapse\1 month were sta-
tistically significantly associated with increased
mortality. Aggressive NHL was associated with
a 2.29-fold increased risk of death compared with in-
dolent NHL (95% CI, 1.24-4.23; P 5 .008), whereas
mortality was not statistically significantly different
for HL and indolent NHL (HR, 1.21; 95% CI, 0.60-
2.42; P 5 .59). Likewise, patients who relapsed within
1 month after allogeneic HCT had a 3.17-fold greater
risk of death compared with those who relapsed after 6
months (P 5 .004), whereas there was no statistically
significant difference in the risk of mortality for pa-
tients who relapsed at intermediate intervals after
HCT.Relapse Intervention and Disease Control
A total of 87 patients (86%) received interventions
for disease progression (Figure 4) including with-
drawal of IST alone (n 5 11), chemotherapy or radio-
therapy (n 5 60), and DLI and/or a second allogeneic
HCT (n 5 16). Among the subgroup of 13 patients
who relapsed with minimal disease, 11 patients under-
went withdrawal of IST alone (n 5 5), chemotherapy
or radiotherapy (n 5 4), or DLI and/or a second allo-
geneic HCT (n 5 2).
Responses to the initial intervention were observed
in 19 of 36 patients with aggressive NHL (53%), in 20
of 28 patients with indolent NHL (71%), and in 18 of
23 (78%) patients with HL. Twenty-seven patients
(75%) with aggressive NHL and 15 (54%) with indo-
lent NHL receiving postrelapse intervention died,
with a median OS of 5.6 months and 30.5 months, re-
spectively. ThemedianOS of patients withHL treated
for relapse was 33.2 months, with 15 patients (65%)
dying by last contact.
Table 2. Univariate and Multivariate Analyses for Factors
Associated with Mortality for 101 Lymphoma Patients Who
Relapsed after RIC with Allogeneic HCT
Factor HR 95% CI P
Univariate analysis
HCT-CI* 0.92 0.75-1.13 .43
Histology†
Aggressive histology 2.79 1.55-5.01 .0006
Hodgkin lymphoma 1.07 0.55-2.08 .84
No BM involvement 0.87 0.54-1.42 .58
Chemoresponsive disease 0.65 0.40-1.05 .08
Last previous remission duration* 0.62 0.33-1.17 .14
Pretransplantation maximal bulk of
disease
1.05 0.91-1.19 .52
Number of previous regimens* 1.03 0.87-1.23 .68
Non-MRD 1.50 0.93-2.42 .10
Acute GVHD before relapse 0.96 0.59-1.55 .87
Chronic GVHD before relapse 0.50 0.27-0.94 .03
Time to relapse* 0.95 0.91-0.99 .02
Time to relapse‡
<1 month 4.30 2.11-8.78 <.0001
1-3 months 1.46 0.76-2.8 .25
3-6 months 1.16 0.55-2.47 .69
Multivariate analysis§
Histology†
Aggressive histology 2.29 1.24-4.23 .008
Hodgkin lymphoma 1.21 0.60-2.42 .59
Time to relapse‡
<1 month 3.17 1.45-6.93 .004
1-3 months 1.28 0.64-2.56 .49
3-6 months 1.15 0.54-2.45 .71
Chronic GVHD before relapse 0.24 0.03-1.73 .16
Chemoresponsive disease 0.69 0.38-1.21 .20
BM indicates bone marrow; MRD, matched related donor.
*Modeled as a continuous linear variable. HR represents increase in haz-
ard associated with increase in 1 unit, where 1 unit for time to relapse
and remission duration is 1 month.
†Reference group is indolent histology.
‡Reference group is relapse >6 months.
§All of the univariate factors were included in the initial model, but only
those that independently contributed were included in the final multivar-
iate model: histology, time to relapse, chronic GVHD before relapse,
and chemoresponsive disease.
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continued to predict outcomes in patients who re-
sponded to the initial postrelapse intervention. For ex-
ample, among patients who responded to their initial
interventions (n 5 57), those who relapsed within 1
month of HCT were more likely to progress again
(HR, 2.69; 95% CI, 1.04-6.95; P 5 .04) and die (HR,
4.45; 95% CI, 1.43-13.87; P 5 .01) compared with
those who relapsed more than 6 months after HCT.
Similarly, responding patients with aggressive NHL
had a 3.05-fold greater risk of dying compared with re-
sponding patients with indolent NHL (95% CI, 1.15-
8.13; P 5 .03). In contrast, responding patients with
HL were not statistically significantly more likely to
die than responding patients with indolent NHL
(HR, 1.82; 95% CI, 0.68-4.83; P 5 .23), although
they were 3.27-fold more likely to further progress
compared with responding patients with indolent
NHL (P 5 .008). Postintervention acute GVHD and
chronic GVHD complicated interventions in 47%and in 56% of patients, respectively. Withdrawal of
IST was not sustainable in the majority of patients,
with 60% of patients requiring reinitiation or dosage
increase of IST.Outcomes of Specific Interventions
Withdrawal of IST
Eleven patients who relapsed at a median of 3.7
months (range, 1-12.2 months) after HCT were
treated with withdrawal of IST alone. All patients re-
sponded to the intervention, although 6 had only min-
imal disease at relapse. Seven patients (64%) developed
postintervention GVHD, and 2 died fromGVHD and
related complications. At a median follow-up time of
17.4 months (range, 4.3-97.8 months), 9 patients
were alive and 7 were alive without progression (3 of
4 with aggressive NHL, 3 of 6 with indolent NHL,
and 1 of 1 with HL). Among the 13 patients who pro-
gressed with only minimal disease, 7 (54%) eventually
developed a systemic measurable relapse (4 with indo-
lent NHL and 3 with aggressive NHL), and 6 (4 with
indolent NHL and 2 with aggressive NHL) did not
progress further. Five of the 13 patients (2 with aggres-
siveNHL and 3 with indolentNHL) were treated with
withdrawal of IST alone, and 4 were alive at a median
follow-up of 17 months (range, 4-50 months). One of
the 4 patients who received chemoradiotherapy was
alive at 17 months post-HCT. The 2 patients who re-
ceived DLI died.
Chemotherapy and/or Radiotherapy
Sixty patients who relapsed at a median of 2.9
months (range, 0.1-42.5 months) after allogeneic
HCT were treated with chemotherapy and/or radio-
therapy, and 50 of these patients also underwent with-
drawal of IST. Thirty-six patients (60%) responded to
the intervention. At a median follow-up of 26.6
months (range, 17-56.4 months) from relapse, 16 pa-
tients (27%) were alive (5 of 28 with aggressive
NHL, 6 of 17 with indolent NHL, and 5 of 15 with
HL). Nine of the 60 patients (5 with aggressive
NHL and 4 with indolent NHL) were treated only
with rituximab with or without withdrawal of IST; me-
dian survival for this group was 9.4 months after re-
lapse.
DLI and Second Allogeneic HCT
Fifteen patients received DLI. Median time from
allogeneic HCT to relapse in this group was 5.8
months (range, 1.5-23.3 months), and median time
from relapse to DLI was 3 months (range, 1-8.4
months). Eleven patients received chemotherapy
with or without radiotherapy before DLI, of whom 8
had achieved PR/CR before infusion of donor cells
and 3 had progressive disease. Two patients with HL
Patients with 
disease relapse 
(33/101 alive)
Aggressive 
NHL 
(10/42 alive)
Indolent 
NHL 
(14/33 alive)
Hodgkin 
lymphoma 
(9/26 alive)
Intervention
 (9/36 alive)
No intervention 
(1/6 alive) 
Intervention
 (13/28 alive)
Only withdrawal 
of IST (3/4 
alive) 
Chemotherapy 
and/or 
radiotherapy 
(5/28 alive)
DLI/alloHCT 
(1/4 alive)
No intervention
 (1/5 alive)
Intervention
 (8/23 alive)
Only withdrawal 
of IST 
(5/6 alive) 
Chemotherapy 
and/or 
radiotherapy 
(6/17 alive)
DLI/alloHCT 
(2/5 alive)
Only withdrawal 
of IST 
(1/1 alive) 
Chemotherapy 
and/or 
radiotherapy 
(5/15 alive)
DLI/alloHCT 
(2/7 alive)
No intervention 
(1/3 alive)
Figure 4. Flow chart of relapsed patients after RIC HCT, with interventions and outcomes.
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The 4 patients who did not receive chemotherapy be-
fore receiving DLI demonstrated no response to DLI.
The initial cell dose was 1 107 of CD3 cells/kg in
12 patients (80%). Eleven patients (73%) received 1 in-
fusion, 3 patients (20%) received 2 infusions, and 1 pa-
tient received 3 infusions. Four patients (27%)
developedGVHD, and 6 patients (40%; 1 with aggres-
siveNHL, 2 with indolentNHL, and 3 withHL) dem-
onstrated a response after DLI. At a median follow-up
of 40.4months after relapse (range, 32.9-66.6months),
4 patients (27%; 1 with aggressive NHL, 1 with indo-
lent NHL, and 2 with HL) were alive in CR, 7 (47%)
had died due to relapse, and 4 (27%) had died due to
GVHD or infection.
Three patients (1 each with MZL, DLBCL, and
HL) underwent a second allogeneic HCT from an al-
ternate donor; 2 of these patients had failed previous
DLI. Two patients received a matched unrelated graft
and were conditioned with 2-4 Gy TBI and fludara-
bine 30 mg/m2, for 3 consecutive days. One patient re-
ceived a haploidentical graft and was conditioned with
low-dose TBI, fludarabine, and cyclophosphamide.
None of these patients are currently alive, despite the
fact that 2 of the 3 patients relapsed more than 1 year
after the first allogeneic HCT. These patients died at
2.2 months, 8 months, and 8.9 months after a second
HCT, with all deaths attributed to transplantation-
associated complications.Patients Not Undergoing Intervention
for Relapse
Fourteen patients (14%) did not receive any inter-
ventions after relapse. The 6 patients with aggressive
NHL had measurable recurrences less than 1.2
months after transplantation; all 6 of these patients
died, with a median postrelapse survival of 1 month
(range, 0.7-10 months). Median time to relapse was
2.9 months (range, 2.8-6.1 months) for the 5 patients
with indolent NHL and 8.8 months (range, 3.6-12
months) for the 3 patients with HL. Two patients
(1 with CLL and 1 with HL) were alive at 83.7 months
and 37 months after relapse, respectively.DISCUSSION
Herewe have reported the characteristics,manage-
ment, and outcomes of 101 consecutive patients with
lymphoma or CLL who relapsed after RIC HCT
over the past decade at our center. The findings of
this study, the largest series reported to date with de-
tailed follow-up of these patients, illustrates a number
of key points. First, relapse typically occurs early after
HCT (median, 3 months) and is most pronounced in
patients with aggressive NHL (median, 1.3 months),
as has been suggested by others [24,25]. Both early
relapse and aggressive disease are associated with
inferior survival, lending support to the view that at
Biol Blood Marrow Transplant 17:1537-1545, 2011 1543Lymphoma Relapse after RIC Allogeneic HCTleast a few months of disease control is necessary for
a significant GVL effect to emerge [11,25-27]. These
data imply that strategies aimed at improving disease
control immediately before or after HCT may yield
considerably improved outcomes. Conversely, late
relapses, indolent histology, and HL were associated
with improved survival, likely reflecting the slower
tumor growth kinetics and the reported GVL effect
in these diseases [2,28]. Importantly, our data indicate
that prolonged survival is possible for patients with
late relapse, indolent NHL, or HL despite relapse
after RIC HCT.
Our reports of outcomes of all patients who re-
lapsed illustrate the potential selection that occurs
when describing the results of specific postrelapse in-
tervention. For example, DLI was offered only to 15
patients who relapsed nearly 3 months later than the
median time and survived a median of 3 additional
months from relapse to DLI. However, evaluating
this subset only showed that 40% of those treated re-
sponded, with some achieving a durable long-term
survival, similar to rates reported in the literature
[10,29]. Likewise, withdrawal of IST with or without
other therapies was sustainable in less than half of
the cases, suggesting that this approach might not be
feasible for maintaining long-term remission in most
patients. Finally, only 9 patients received single-
agent rituximab, and none of those with aggressive
NHL responded or survived.
These data are critical when counseling patients
about the realistic long-term strategies for dealing
with relapse. Unfortunately, determining the optimal
approach for relapsing patients is a more difficult chal-
lenge. Although the majority of the relapsing patients
(86%) received some intervention, treatment decisions
likely were based on such factors as time to relapse, his-
tology, previous therapies, disease burden, comorbid-
ities, and GVHD, as well as on response to the initial
intervention. As such, the results of treatment inter-
vention in our series should be considered descriptive
and should not be interpreted as recommendations.
Nonetheless, our focus on patients who responded
to initial postrelapse treatment illuminates factors asso-
ciated with presumably GVL-related long-term dis-
ease control. In this group of responding patients,
those with HL had a .3-fold greater risk of further
progression relative to patients with indolent NHL,
despite a longer time to initial relapse. These findings
corroborate previous studies reporting high relapse
and progression rates in patients with HL undergoing
HCT with RIC or nonmyeloablative conditioning
[29-31]. Even among responders, those who relapsed
less than 1 month after HCT were at greater risk for
further progression, possibly attributed to tumor
kinetics and ineffective GVL [4,32]. It is interesting
and encouraging that a subset of patients with
aggressive NHL not only responded to interventions,but also in some cases achieved long-term survival, pre-
sumably via GVL-mediated disease control.
In summary, this first large analysis of relapse after
RIC HCT for lymphoma has yielded clinically rele-
vant data. Two-thirds of patients who received an in-
tervention had meaningful responses, with 23%
surviving at 5 years and even better outcomes in pa-
tients with indolent NHL and later relapse. Nonethe-
less, it is critical that patients and treatment providers
recognize the grave prognosis of patients with aggres-
siveNHLwho relapse within 1month of HCT and se-
riously consider palliative care or novel experimental
agents for these patients. Future prospective trials
should focus on reducing the risk of early relapse and
improving long-term disease control in individuals
with aggressive NHL. Finally, patients with HL have
the greatest likelihood of disease progression even af-
ter response to an initial intervention, suggesting the
need for innovative strategies to maintain remission
in this setting [33]. Unfortunately, however, although
the potential for long-term disease control remains
a possibility, the majority of patients will succumb to
the disease and never receive interventions such as
DLI or second HCT. We hope that our findings can
aid both treating physicians in counseling relapsing pa-
tients and investigators in creatively addressing this
clinical challenge.ACKNOWLEDGMENTS
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